Sanofi Canada

About Sanofi

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.

Sanofi is the largest biopharma manufacturer in Canada, and the only company investing, innovating and operating across the full life sciences value chain. We are 2,000+ employees strong, invest 20% of our revenue annually in biopharma research, and are on track to deliver over $2 billion in new infrastructure investments by 2028. Sanofi is committed to our community and is working with partners to foster a long-term sustainable ecosystem and build a healthier Canada.

Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.

Latest

Mar 21, 2023, 08:00 ET Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)

TORONTO, March 21, 2023 /CNW/ - sanofi-aventis Canada Inc. (Sanofi Canada) is pleased to announce that Health Canada has issued a Notice of Compliance ("NOC") for Rezurock™ (belumosudil tablets), for ...

Mar 08, 2023, 09:28 ET Sanofi Canada Maintains Gender Parity Certification, Achieving Platinum Level

The certification recognizes the outstanding commitments and actions of companies to achieve gender parity at all levels of business. Sanofi has committed to reaching gender parity amongst the...

Jan 18, 2023, 08:00 ET Health Canada accepts nirsevimab regulatory submission for infant RSV

Nirsevimab is the first investigational long-acting antibody designed for all infants to help protect against respiratory syncytial virus (RSV) throughout their first RSV season with a single dose...

Oct 26, 2022, 08:00 ET Canadians Encouraged to Live "In Range" to Better Manage their Diabetes

Monitoring Time in Range helps minimize fluctuating blood sugar levels, mitigates complications of diabetes LAVAL, QC, Oct. 26, 2022 /CNW/ - Soon after the onset of the COVID-19 pandemic, it became...

Jul 05, 2022, 08:00 ET Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Skyhawk Therapeutics, Inc. today announced the signing of an exclusive worldwide collaboration agreement with Sanofi to discover and develop novel small molecules that modulate RNA splicing for...

Jun 22, 2022, 08:04 ET Sanofi to Launch Artificial Intelligence Centre of Excellence in Toronto

TORONTO, June 22, 2022 /CNW Telbec/ - Sanofi is pleased to announce the opening of an Artificial Intelligence Centre of Excellence in Toronto, joining Sanofi's global network of existing digital hubs ...

Jun 16, 2022, 08:31 ET Sanofi Canada awards second annual Sanofi Biogenius Canada Grants, supporting access to hands-on STEM learning for Canadian students

LAVAL, QC, June 16, 2022 /CNW Telbec/ - Sanofi Canada is pleased to award four, $50,000 Sanofi Biogenius Canada Grants to public high schools from across the country to help provide better access to...

Jun 15, 2022, 08:00 ET Sanofi Canada announces winners of 2022 Sanofi Biogenius Canada Competition

LAVAL, QC, June 15, 2022 /CNW Telbec/ - Sanofi Canada is pleased to announce that the winners of the 30th annual Sanofi Biogenius Canada Competition have been selected. This year's Competition took...

Jun 14, 2022, 08:00 ET Sanofi Canada furthers commitment to Canadians living with diabetes through mental health resources provided by MindBeacon

Providing online access to critical mental health support enables 360-degree approach to diabetes management beyond medication LAVAL, QC, June 14, 2022 /CNW Telbec/ - Since the onset of the COVID-19...

May 10, 2022, 09:00 ET Sanofi Biogenius Canada Competition returns to Canada-Wide Science Fair

LAVAL, QC, May 10, 2022 /CNW/ - Sanofi Canada is proud to partner with Youth Science Canada (YSC) for the 30th annual Sanofi Biogenius Canada Competition, which will take place during the 60th...

May 03, 2022, 09:06 ET Sanofi achieves the third year of Gold-level Gender Parity Certification

The certification recognizes the outstanding commitments and actions of companies to achieve gender parity at all levels of business. Sanofi has committed to reaching gender parity amongst the...

Mar 28, 2022, 08:00 ET Dupixent® (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation

This is the sixth indication for Dupixent in Canada, its second in asthma, and its second in children aged six to 11 yearsi Dupixent is the only biologic approved in Canada to treat severe asthma...

Mar 25, 2022, 15:20 ET Libtayo® (cemiplimab) now approved in Canada for the treatment of recurrent or metastatic cervical cancer

Fourth Canadian approval of Libtayo in difficult-to-treat cancers MISSISSAUGA, ON, March 25, 2022 /CNW Telbec/ - Today sanofi-aventis Canada Inc. (Sanofi) announced the approval of Libtayo®...

Jan 25, 2022, 13:49 ET Sanofi Canada named one of Forbes Canada's Best Employers for 2022

Reinforces Sanofi Canada's commitment to inclusion and diversity, STEM equity and scientific innovation LAVAL, QC, Jan. 25, 2022 /CNW/ - For the second year in a row, Sanofi Canada has been named one ...

Dec 09, 2021, 13:00 ET Sanofi Canada supports Canada's Walk of Fame in its induction of Frederick Banting, Charles Best, James Collip and John Macleod in the 100th anniversary year of their discovery of insulin

LAVAL, QC, Dec. 9, 2021 /CNW/ - Marking 100 years since the discovery of insulin at Connaught Laboratories, the predecessor of Sanofi Canada, the researchers responsible for the diabetes drug –...

Nov 15, 2021, 09:00 ET Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for patients with late-onset Pompe disease (acid α-glucosidase deficiency)

MISSISSAUGA, ON, Nov. 15, 2021 /CNW/ - Nexviazyme™ (avalglucosidase alfa for injection) is now approved in Canada for the long-term treatment of patients older than 6 months of age with late-onset...

Nov 10, 2021, 08:15 ET Canadians living with diabetes want increased mental health resources, are interested in taking a 360-approach towards holistic care

Ahead of World Diabetes Day, Sanofi Canada releases market research that explores the care journey for Canadians living with diabetes LAVAL, QC, Nov. 10, 2021 /CNW/ - Forty per cent of Canadians...

Oct 29, 2021, 07:00 ET Libtayo® (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients

The approval is based on data from the open-label, multi-center, non-randomized Study 16201 MISSISSAUGA, ON, Oct. 29, 2021 /CNW/ - Libtayo® (cemiplimab) is now approved in Canada for the treatment of ...

Oct 29, 2021, 07:00 ET Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in ≥ 50% of tumour cells with no EGFR, ALK or ROS1 aberrations

The approval is based on data from the randomized, open-label, multi-center Study 16241 MISSISSAUGA, ON, Oct. 29, 2021 /CNW/ - Libtayo® (cemiplimab) is now approved in Canada for the first-line...

Oct 13, 2021, 06:10 ET New SARCLISA® (isatuximab for injection) Combination Now Approved by Health Canada for Adults with Relapsed and/or Refractory Multiple Myeloma

The approval is based on data from the Phase 3 IKEMA study.1,2 Multiple myeloma (MM) is the third most common blood cancer in Canada, with an estimated 3300 new cases diagnosed in 2019.3 MISSISSAUGA, ...

Jul 22, 2021, 12:00 ET DUPIXENT® (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma

Recommendation supported by multiple clinical trials that demonstrated a reduced frequency of asthma exacerbations compared to placebo, and a reduction in the need for oral corticosteroids in oral...

Jul 02, 2021, 10:00 ET Sanofi Canada continues to invest in modern diabetes research to improve outcomes for people living with diabetes

* Multiple Canadian research studies were presented at the 81st Annual American Diabetes Association Scientific Sessions to identify optimal therapies for sustained diabetes management and remission. ...

Jun 28, 2021, 13:28 ET New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin

Study also shows more people on Soliqua had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin...

Jun 17, 2021, 10:00 ET DUPIXENT® (dupilumab injection) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases

DUPIXENT® is approved by Health Canada for use in moderate-to-severe atopic dermatitis, severe chronic rhinosinusitis with nasal polyposis and severe asthma.1 The pre-filled pen offers an additional...

Jun 10, 2021, 14:00 ET Sanofi Canada awards first annual Biogenius Grants, strengthening equity in STEM learning for Canadian students

Inaugural Sanofi Biogenius Grant awarded to four diverse secondary schools across Canada to revitalize science education for their students. Driving towards Science, Technology, Engineering &...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.